KZIA
Kazia Therapeutics Limited
NASDAQ · Healthcare · Biotechnology · AU
$12.48
+2.63%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.8x
Market Cap
$174.81M
MomentumView details →
1D Return
+2.63%
YTD Return
+80.26%
RSI (14)
44.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.8x
Market Cap
$174.81M
RSI (14)
44.6
MomentumView details →
1D Return
+2.63%
YTD Return
+80.26%
SummaryUpdated Dec 1, 2025
Kazia Therapeutics Limited (NASDAQ:KZIA) is an Australian oncology-focused biotechnology company that develops anti-cancer drugs for treating various forms of cancer. Originally incorporated in 1994 as Novogen Limited, the company rebranded to Kazia Therapeutics in November 2017 to better reflect its focus on cancer therapeutics. Based in Sydney, Australia, Kazia went public in 1999 and has been dedicated to advancing novel cancer treatments through clinical development, with particular emphasis on brain-penetrant therapies for difficult-to-treat cancers like glioblastoma.
Similar companies
Latest newsMore news →
Kazia Therapeutics expanded its paxalisib clinical trial into HR+/HER2- breast cancer.3d agoKazia Therapeutics Limited announced a tranched registered public offering of American Depositary Shares, pre-funded warrants, and accompanying Series A and Series B warrants to purchase ADSs.8d agoKazia Therapeutics announced new clinical data for its lead asset paxalisib in advanced triple-negative breast cancer, reporting a 100% clinical benefit rate in six evaluable patients.8d ago